1252 related articles for article (PubMed ID: 21289970)
1. Therapy of atopic eczema.
Werfel T; Claes C; Kulp W; Greiner W; von der Schulenburg JM
GMS Health Technol Assess; 2006 Oct; 2():Doc19. PubMed ID: 21289970
[TBL] [Abstract][Full Text] [Related]
2. Therapy of moderate and severe psoriasis.
Claes C; Kulp W; Greiner W; von der Schulenburg JM; Werfel T
GMS Health Technol Assess; 2006 Apr; 2():Doc07. PubMed ID: 21289958
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis.
Fröschl B; Arts D; Leopold C
GMS Health Technol Assess; 2007 Sep; 3():Doc09. PubMed ID: 21289943
[TBL] [Abstract][Full Text] [Related]
4. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
5. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.
Green C; Colquitt JL; Kirby J; Davidson P; Payne E
Health Technol Assess; 2004 Nov; 8(47):iii,iv, 1-120. PubMed ID: 15527669
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
7. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
[TBL] [Abstract][Full Text] [Related]
8. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(27):1-66. PubMed ID: 23074532
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Breuer K; Werfel T; Kapp A
Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.
Garside R; Stein K; Castelnuovo E; Pitt M; Ashcroft D; Dimmock P; Payne L
Health Technol Assess; 2005 Jul; 9(29):iii, xi-xiii,1-230. PubMed ID: 16022804
[TBL] [Abstract][Full Text] [Related]
11. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Wellington K; Jarvis B
Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic, prophylactic and therapeutic guidelines in patients with atopic dermatitis. Position paper by the task force of the National Specialists on Dermatology, Venereology and Allergology].
Gliński W; Kruszewski J; Silny W; Kurzawa R; Czarnecka-Operacz M; Baran E; Szepietowski J;
Pol Merkur Lekarski; 2004; 17 Suppl 3():3-15. PubMed ID: 15688665
[TBL] [Abstract][Full Text] [Related]
14. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.
Wollenberg A; Christen-Zäch S; Taieb A; Paul C; Thyssen JP; de Bruin-Weller M; Vestergaard C; Seneschal J; Werfel T; Cork MJ; Kunz B; Fölster-Holst R; Trzeciak M; Darsow U; Szalai Z; Deleuran M; von Kobyletzki L; Barbarot S; Heratizadeh A; Gieler U; Hijnen DJ; Weidinger S; De Raeve L; Svensson Å; Simon D; Stalder JF; Ring J;
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2717-2744. PubMed ID: 33205485
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of treatments for atopic eczema.
Hoare C; Li Wan Po A; Williams H
Health Technol Assess; 2000; 4(37):1-191. PubMed ID: 11134919
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on topical pimecrolimus in atopic dermatitis.
Wellington K; Jarvis B
Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
[TBL] [Abstract][Full Text] [Related]
18. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.
Devasenapathy N; Chu A; Wong M; Srivastava A; Ceccacci R; Lin C; MacDonald M; Wen A; Steen J; Levine M; Pyne L; Schneider L; Chu DK;
Lancet Child Adolesc Health; 2023 Jan; 7(1):13-25. PubMed ID: 36370744
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Abramovits W; Hung P; Tong KB
Am J Clin Dermatol; 2006; 7(4):213-22. PubMed ID: 16901181
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
